Fluticasone furoate

Drug Profile

Fluticasone furoate

Alternative Names: 685698; Allermist; Aramisuto; Arnuity Ellipta; Avamys; GW-685698; GW-685698X; Veramyst

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Androstadienes; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Perennial allergic rhinitis; Seasonal allergic rhinitis
  • No development reported Rhinosinusitis

Most Recent Events

  • 09 Dec 2016 GlaxoSmithKline plans a phase II trial for Asthma in United Kingdom (NCT02991859)
  • 31 Aug 2016 GlaxoSmithKline plans a phase IV trial for Asthma in USA, South Africa, Romania, Russia, Poland and Argentina (NCT02889809)
  • 01 Jun 2016 GlaxoSmithKline completes phase-III clinical trials in Asthma (In children) in USA and South Africa (Inhalation) (NCT02483975)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top